


## Repaglinide-d<sub>5</sub>

<b>Cat. No.:</b>	HY-15209S		
<b>CAS No.:</b>	1217709-85-7		
<b>Molecular Formula:</b>	C <sub>27</sub> H <sub>31</sub> D <sub>5</sub> N <sub>2</sub> O <sub>4</sub>		
<b>Molecular Weight:</b>	457.62		
<b>Target:</b>	Potassium Channel; Isotope-Labeled Compounds		
<b>Pathway:</b>	Membrane Transporter/Ion Channel; Others		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (218.52 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.1852 mL	10.9261 mL	21.8522 mL
	5 mM	0.4370 mL	2.1852 mL	4.3704 mL
	10 mM	0.2185 mL	1.0926 mL	2.1852 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Repaglinide-d<sub>5</sub> is deuterium labeled Repaglinide. Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus[1].

#### In Vitro

Repaglinide reduces postprandial glucose levels by enhancing the early phase of insulin secretion and increasing the total amount of insulin secreted<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Wang LC, et al. Characteristics of repaglinide and its mechanism of action on insulin secretion in patients with newly diagnosed type-2 diabetes mellitus. *Medicine* (Baltimore). 2018 Sep;97(38):e12476.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA